2. >>Policy & Regulation

J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed

 
• By Reed Miller

Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.

Abiomed’s Impella 5.0 Heart Pump Transcatheter Circulatory Support Device
Abiomed's Impella Circulatory Support Device • Source: Abiomed

[Editor's Note: Due to a technical issue, some of this article did not appear online when it was originally published on 1 November, so we are republishing it in its entirety.]

Johnson & Johnson will pay at least $16

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation